These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9133074)

  • 21. Current issues in dendritic cell cancer immunotherapy.
    López JA; Hart DN
    Curr Opin Mol Ther; 2002 Feb; 4(1):54-63. PubMed ID: 11885565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide.
    Hino M; Kohchi C; Nishizawa T; Yoshida A; Nakata K; Inagawa H; Hori H; Makino K; Terada H; Soma G
    Anticancer Res; 2005; 25(6A):3747-54. PubMed ID: 16302735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interstitial quinacrine activates a distinctive immune response effective for tumor immunotherapy.
    Sotelo J; Guevara P; Pineda B; Diaz C
    Surgery; 2004 Sep; 136(3):700-7. PubMed ID: 15349121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cells as natural adjuvants.
    Citterio S; Rescigno M; Foti M; Granucci F; Aggujaro D; Gasperi C; Matyszak MK; Girolomoni G; Ricciardi-Castagnoli P
    Methods; 1999 Sep; 19(1):142-7. PubMed ID: 10525450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letter: Immunotherapy inaccuracy.
    Gray BN
    Med J Aust; 1975 Dec; 2(23):887. PubMed ID: 1219344
    [No Abstract]   [Full Text] [Related]  

  • 28. Functions of natural killer cells.
    Vivier E; Tomasello E; Baratin M; Walzer T; Ugolini S
    Nat Immunol; 2008 May; 9(5):503-10. PubMed ID: 18425107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview: immunotherapy for cancer--is it time for the kitchen sink?
    Davis TA
    Curr Opin Investig Drugs; 2002 Jan; 3(1):130-1. PubMed ID: 12054063
    [No Abstract]   [Full Text] [Related]  

  • 30. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.
    Schreiber K; Rowley DA; Riethmüller G; Schreiber H
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):567-84. PubMed ID: 16762725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer.
    Snyder LL; Woo DV; Triozzi PL; Stevens VC
    Pharm Biotechnol; 1995; 6():907-30. PubMed ID: 7551255
    [No Abstract]   [Full Text] [Related]  

  • 32. Adjuvant histamine in cancer immunotherapy.
    Hellstrand K; Hansson M; Hermodsson S
    Semin Cancer Biol; 2000 Feb; 10(1):29-39. PubMed ID: 10888269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The use of autovaccines prepared on a base of microbial synthesis products for the stimulation of body antitumor resistance].
    Shalimov SA; Potebnia GP; Keĭsevich LV; Litvinenko AA; Lisovenko GS; Koval'chuk AV; Kot LN; Shumilina VV
    Klin Khir (1962); 1994; (5):69-73. PubMed ID: 7807914
    [No Abstract]   [Full Text] [Related]  

  • 34. The anti-idiotype vaccines for immunotherapy.
    Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
    Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolution of antibodies into versatile tumor-targeting agents.
    Lin MZ; Teitell MA; Schiller GJ
    Clin Cancer Res; 2005 Jan; 11(1):129-38. PubMed ID: 15671537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The metastasis of malignant tumors--the therapeutic problem].
    Timcheva K; Todorov D
    Vutr Boles; 1991; 30(1):26-31. PubMed ID: 1771856
    [No Abstract]   [Full Text] [Related]  

  • 37. [Carcinogenesis and immunobiology of tumors. Scientific and clinical aspects].
    Granov AM; Molchanov OE
    Vopr Onkol; 2008; 54(4):401-9. PubMed ID: 18942393
    [No Abstract]   [Full Text] [Related]  

  • 38. Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration.
    Bernsen MR; Tang JW; Everse LA; Koten JW; Otter WD
    Cancer Treat Rev; 1999 Apr; 25(2):73-82. PubMed ID: 10395833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte-macrophage colony-stimulating factor gene-modified vaccines for immunotherapy of cancer.
    Bubeník J
    Folia Biol (Praha); 1999; 45(4):115-9. PubMed ID: 10732724
    [No Abstract]   [Full Text] [Related]  

  • 40. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.